Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature
Abstract Background Pembrolizumab, a PD-1 inhibitor, is widely used for treating advanced cancers, including metastatic non-small cell lung cancer (NSCLC). However, its use can lead to immune-related adverse events (IRAEs), including cutaneous manifestations such as bullous pemphigoid (BP). Case pre...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-025-02377-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|